Literature DB >> 10385077

Evidence for epitope spreading and active suppression in skin graft tolerance after donor-specific transfusion.

L Yang1, B DuTemple, R M Gorczynski, G Levy, L Zhang.   

Abstract

BACKGROUND: To clarify the controversial results in the literature regarding the role of donor-specific transfusion (DST) on allograft survival, we have examined the influence of the following on DST-induced allograft survival in a 2C transgenic mouse model: varying the time between DST and transplantation; the role of MHC disparities between donor and recipient; whether tolerance induced by DST spreads to skin allografts expressing other alloantigens; and whether cyclosporine (CsA) treatment could further modulate skin allograft tolerance after DST. METHODS AND
RESULTS: The studies were performed in both 2C anti-Ld (MHC class I) transgenic and normal (nontransgenic) mice. Our data demonstrate that a single infusion of Ld-mismatched lymphocytes 7 days before transplantation leads to permanent acceptance of donor-specific skin allografts in both transgenic (58/58) and nontransgenic (8/8) mice in the absence of any other nonspecific immunosuppressive treatment. Pretransplantation DST from donors mismatched for more than one MHC antigen (Ag) has no beneficial effect on subsequent donor skin allograft survival. However, Ld plus multiple minor histocompatibility (mH) Ag-mismatched DST induced permanent acceptance of donor-specific skin allografts. Tolerance induced by one-locus Ld-mismatched DST spreads to skin allografts expressing either two-locus Ld or one-locus Ld plus multiple mH Ags. Administration of CsA after DST diminished skin allograft survival, rather than enhancing it, suggesting that tolerance in this model system is established by an active immunological process sensitive to CsA.
CONCLUSIONS: (1) Pretransplantation infusion of Ld-mismatched lymphocytes in the presence or absence of multiple mH mismatches induces permanent survival of donor-specific skin allografts. (2) CsA abrogates DST-induced transplantation tolerance.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10385077     DOI: 10.1097/00007890-199906150-00003

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  6 in total

1.  New differentiation pathway for double-negative regulatory T cells that regulates the magnitude of immune responses.

Authors:  Dong Zhang; Wei Yang; Nicolas Degauque; Yan Tian; Allison Mikita; Xin Xiao Zheng
Journal:  Blood       Date:  2006-12-29       Impact factor: 22.113

Review 2.  T regulatory cells and transplantation tolerance.

Authors:  Vijay S Gorantla; Stefan Schneeberger; Gerald Brandacher; Robert Sucher; Dong Zhang; W P Andrew Lee; Xin Xiao Zheng
Journal:  Transplant Rev (Orlando)       Date:  2010-06-11       Impact factor: 3.943

3.  The role of CD154-CD40 versus CD28-B7 costimulatory pathways in regulating allogeneic Th1 and Th2 responses in vivo.

Authors:  K Kishimoto; V M Dong; S Issazadeh; E V Fedoseyeva; A M Waaga; A Yamada; M Sho; G Benichou; H Auchincloss; M J Grusby; S J Khoury; M H Sayegh
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

4.  Ethylenecarbodiimide-fixed donor splenocyte infusions differentially target direct and indirect pathways of allorecognition for induction of transplant tolerance.

Authors:  Taba Kheradmand; Shusen Wang; Jane Bryant; James J Tasch; Nadine Lerret; Kathryn L Pothoven; Josetta L Houlihan; Stephen D Miller; Zheng J Zhang; Xunrong Luo
Journal:  J Immunol       Date:  2012-06-13       Impact factor: 5.422

Review 5.  Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure?

Authors:  Richard K Burt; Shimon Slavin; William H Burns; Alberto M Marmont
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.319

6.  Immunoregulatory CD4(-)CD8(-) T cells as a potential therapeutic tool for transplantation, autoimmunity, and cancer.

Authors:  Erin E Hillhouse; Jean-Sébastien Delisle; Sylvie Lesage
Journal:  Front Immunol       Date:  2013-01-24       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.